Aprocitentan(CAS:1103522-45-7)

Aprocitentan, CAS number 1103522-45-7, is an innovative dual endothelin receptor antagonist API with a brand-new antihypertensive pathway approved by FDA in 2024, branded as Tryvio. It fills the long-standing clinical treatment gap for resistant hypertension and owns extremely high scarcity value in global cardiovascular new drug R&D and generic drug manufacturing, listed as preferred fourth-line therapeutic raw material in hypertension guidelines of multiple countries. It appears as white to off-white crystalline powder with low water solubility and stable chemical structure. Strict control over chiral impurities, related substances and heavy metals makes it fully compliant with European and US pharmacopoeia standards. It supports industrial mass production of oral film-coated tablets and meets diverse demands including new drug application, bulk preparation export and scientific research experiments.

In terms of core pharmacological mechanism, Aprocitentan targets the human endothelin system, whose overactivation serves as the key pathogenic factor for salt-sensitive, obese, elderly and sleep apnea-related resistant hypertension. Endothelin-1, the most potent endogenous vasoconstrictive peptide, continuously triggers vascular smooth muscle contraction, vascular hypertrophy, sodium-water retention and sympathetic hyperactivity, which cannot be intervened by traditional RAAS inhibitors, calcium channel blockers or beta blockers. Aprocitentan potently blocks both ETA and ETB endothelin receptors with higher affinity for ETA, fundamentally restraining endothelin-1 induced vasoconstriction, inflammation and fibrosis to reduce systemic peripheral vascular resistance for stable blood pressure reduction. It alleviates vascular remodeling and protects vascular endothelium to slow atherosclerosis progression, delivering dual benefits of hypotension and target organ protection. Featuring unique metabolic pathways and a long half-life of 41 hours, it reaches steady-state blood concentration after 8 days of administration. Once-daily dosing realizes 24-hour stable blood pressure control with minimal risks of drug-drug interactions and loose clinical combination restrictions.

Clinically, Aprocitentan is exclusively indicated for adult patients with resistant hypertension, defined as patients failing to reach blood pressure targets after standardized full-dose therapy with three antihypertensives of distinct mechanisms including diuretics, and it can act as fourth or fifth-line combination therapy to lower blood pressure and cut cardiovascular event risks. The landmark Phase 3 PRECISION trial verified that adding Aprocitentan to original triple antihypertensive regimens achieves significant systolic blood pressure reduction within 4 weeks with long-lasting efficacy that persists for weeks after drug withdrawal, showing outstanding curative effect on hypertensive patients complicated with diabetic nephropathy, obesity and elderly comorbidities. Different from macitentan only indicated for pulmonary arterial hypertension, Aprocitentan is specially developed for systemic hypertension with differentiated indications and broader market application scenarios. It can be freely combined with diuretics, calcium channel blockers, ACEIs, ARBs and beta blockers to amplify synergistic antihypertensive effects and lower adverse reactions caused by high single-drug dosage.

Regarding industrial production and clinical safety, Aprocitentan adopts optimized mature synthetic technology with uniform batch purity and low impurity limits, enabling controllable mass production costs and sustainable large-scale manufacturing for pharmaceutical factories. The standard clinical daily doses are 12.5mg and 25mg with favorable overall tolerance. Only mild fluid retention and slight transaminase fluctuations occur in a small number of patients, which can be effectively managed via regular liver and kidney function monitoring. It carries embryo-fetal toxicity risk, so effective contraception is mandatory for women of childbearing age, with safety warnings directly applicable to finished drug instructions. As a landmark novel antihypertensive API, Aprocitentan makes up for the mechanism blind spot of traditional antihypertensive drugs. With rising global diagnosis and treatment demands for resistant hypertension, it holds irreplaceable competitiveness in high-end generic drugs and innovative drug research, promising sustainable broad market prospects in the global pharmaceutical industry.